Claim Amendments

1. (currently amended) A compound of Formula (I)



(I)

or a pharmaceutically acceptable salt or solvate thereof

wherein

A^1 and A^2 are each independently C_{1-4}alkylene or a bond;

A^3 is C_{1-4}alkylene or C_{1-4}alkylidene;

A^4 is C_{1-4}alkylene or a bond and is attached to X, X^1 or X^2;

X, X^1, X^2 and X^3 are independently C or CH;

J is C_{1-4}alkyl;

p is 0 ~~or 1~~;

R^1 and R^2 are independently H, C_{1-3}alkyl, C_{3-6}cycloalkyl, phenyl, -O-phenyl, -N(H)C(O)O-C_{1-4}alkyl or C_{1-4}alkyl-N(H)C(O)O-;

said C_{3-6}cycloalkyl, phenyl or O-phenyl being independently and optionally substituted with C_{1-4}alkyl, C_{1-3}alkoxy or halo;

~~or are independently selected from the group of heterocyclic moieties consisting of thienyl, furanyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, pyridyl, pyrimidinyl, piperidinyl, piperazinyl, morpholino, adamantyl, indolyl, isoindolyl, indolinyl, quinolinyl, dihydroquinolinyl, tetrahydroquinolinyl, isoquinolinyl, dihydroisoquinolinyl and tetrahydroisoquinolinyl, wherein said heterocyclic moieties are optionally substituted with halo, C_{1-4}alkyl, C_{1-4}alkoxy or cyano;~~

~~or wherein A^1-R^1 and A^2-R^2 together with the nitrogen to which they are attached form pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, pyridyl, pyrimidinyl, piperidinyl, piperazinyl, morpholino, adamantyl, indolyl, isoindolyl, indolinyl, quinolinyl, dihydroquinolinyl, tetrahydroquinolinyl, isoquinolinyl, dihydroisoquinolinyl or tetrahydroisoquinolinyl and are optionally substituted with halo, C_{1-4}alkyl, C_{1-4}alkoxy, cyano or benzyl;~~

R^3 is H or C_{1-4}alkyl;

m is 0 or 1;

R^4 and R^5 are independently hydrogen, cyano, halo, nitro or C_{1-3}perfluoroalkyl;

wherein said R^4 or R^5 may be independently attached to X, X^1, X^2 or X^3;

n is 0 or 1;

G is N~~, O or S~~;

G^1 is ~~N or CH~~;

Y is (D)H wherein D is C; and

Z is (E)H wherein E is C;

provided that

both R^4 and R^5 are not attached to the same of said X, X^1, X^2 or X^3;

~~if G is O or S, then m is 0;~~

if G is N, then m is 1;

if R^1 is -N(H)C(O)OC_{1-4}alkyl~~,~~ or C_{1-4}alkyl-N(H)C(O)O~~or said heterocyclic moiety wherein said heterocyclic moiety contains a nitrogen atom and said nitrogen atom is attached to A^1~~, then A^1 is C_{2-4}alkylene;

if R^2 is -N(H)C(O)OC_{1-4}alkyl~~,~~ or C_{1-4}alkyl-N(H)C(O)O~~or said heterocyclic moiety wherein said heterocyclic moiety contains a nitrogen atom and said nitrogen atom is attached to A^2~~, then A^2 is C_{2-4}alkylene;

if R^1 is N(H)C(O)O-C_{1-4}alkyl or~~,~~ C_{1-4}alkyl-N(H)C(O)O~~or a heterocyclic moiety selected from the group consisting of thienyl, furanyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, pyridyl, pyrimidinyl, piperidinyl, piperazinyl, morpholino, adamantyl, indolyl, isoindolyl, indolinyl, quinolinyl, dihydroquinolinyl, tetrahydroquinolinyl, isoquinolinyl, dihydroisoquinolinyl and tetrahydroisoquinolinyl, wherein said heterocyclic moieties are optionally substituted with halo, C_{1-4}alkyl, C_{1-4}alkoxy or cyano~~, then R^2 is H or C_{1-3}alkyl;

if R^2 is ~~-~~N(H)C(O)O-C_{1-4}alkyl~~,~~ or C_{1-4}alkyl-N(H)C(O)O~~or a heterocyclic moiety selected from the group consisting of thienyl, furanyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, pyridyl, pyrimidinyl, piperidinyl, piperazinyl, morpholino, adamantyl, indolyl, isoindolyl, indolinyl, quinolinyl, dihydroquinolinyl, tetrahydroquinolinyl, isoquinolinyl, dihydroisoquinolinyl and~~

~~tetrahydroisoquinolinyl, wherein said heterocyclic moieties are optionally substituted with halo, C_{1-4}alkyl, C_{1-4}alkoxy or cyano,~~ then R^1 is H or C_{1-3}alkyl;

if A^4, R^4 or R^5 are attached to X, then X is C;

if A^4, R^4 or R^5 are attached to X^1, then X^1 is C;

if A^4, R^4 or R^5 are attached to X^2, then X^2 is C;

if R^4 or R^5 are attached to X^3, then X^3 is C;

~~if R^4 is F and is attached to X and if A^3 is methylene, then A^1-R^1 and A^2-R^2 together with the nitrogen to which they are attached is not N-methyl piperazinyl; and~~

~~if R^4 is F and is attached to X and if A^3 is methylene, then A^1-R^1 and A^2-R^2 together with the nitrogen to which they are attached is not tetrahydroquinolinyl.~~

2. (original) A compound according to claim 1 wherein p is 0.
3. (original) A compound according to claim 1 wherein G is N and G^1 is CH.
4. (previously canceled)
5. (previously canceled)
6. (original) A compound according to claim 1 wherein A^1 is a bond, R^1 is methyl, A^2 is a bond and R^2 is methyl.
7. (original) A compound according to claim 1 wherein R^3 is H and m is 1.
8. (previously canceled)
9. (original) A compound according to claim 1 wherein R^4 is hydrogen.
10. (previously canceled)
11. (original) A compound according to claim 1 wherein R^4 is cyano.
12. (previously canceled)
13. (original) A compound according to claim 1 wherein D in relation to the four moieties to which it is attached has an absolute configuration of S; E in relation to the four moieties to

which it is attached has an absolute configuration of S; and wherein the hydrogen atom attached to D is in the *trans* configuration to the hydrogen atom attached to E.

14. (original) A compound according to claim 1 wherein A^3 is C_{1-4}alkylene.
15. (previously canceled)
16. (original) A compound according to claim 1 wherein A^3 is methylene.
17. (original) A compound according to claim 1 wherein wherein A^4 is a bond.
18. (previously canceled)
19. (original) A compound according to claim 1 wherein A^4 is attached X^1.
20. (previously canceled)
21. (original) A compound according to claim 1 wherein R^4 is attached X.
22. (original) A compound according to claim 1 wherein A^1 is a bond, A^2 is a bond, R^1 is methyl and R^2 is methyl.
23. (previously canceled)
24. (previously canceled)
25. (previously canceled)
26. (previously canceled)
27. (original) A compound according to claim 1 wherein R^1 and R^2 are independently H, C_{1-3}alkyl, C_{3-6}cycloalkyl, phenyl, -O-phenyl, or -N(H)C(O)O-C_{1-4}alkyl.
28. (original) A compound according to claim 1 wherein R^1 and R^2 are independently H, C_{1-3}alkyl, or -N(H)C(O)O-C_{1-4}alkyl.
29. (original) A compound according to claim 1 wherein R^1 and R^2 are independently H, C_{1-3}alkyl, C_{3-6}cycloalkyl, phenyl, or -O-phenyl.
30. (canceled)
31. (previously canceled)
32. (previously canceled)
33. (previously canceled)
34. (previously canceled)
35. (previously canceled)
36. (previously canceled)
37. (previously canceled)

38. (previously canceled)

39. (previously canceled)

40. (currently amended) A compound according to claim 1 wherein

A^1 and A^2 are each independently C_{1-4}alkylene or a bond;

A^3 is C_{1-4}alkylene;

A^4 is a bond and is attached to X or X^1;

R^1 and R^2 are independently H, C_{1-3}alkyl, C_{3-6}cycloalkyl, phenyl, -O-phenyl or -N(H)C(O)O-C_{1-4}alkyl;

said C_{3-6}cycloalkyl, phenyl or O-phenyl being independently and optionally substituted with C_{1-4}alkyl, C_{1-3}alkoxy or halo;

~~or are independently selected from the group of heterocyclic moieties consisting of thienyl, imidazolyl, pyridyl, piperidinyl, piperazinyl, morpholino, adamantyl, indolyl, tetrahydroquinolinyl and tetrahydroisoquinolinyl;~~

~~or wherein $-A^1-R^1$ and $-A^3-R^2$ together with the nitrogen to which they are attached form pyrrolidinyl, piperidinyl, piperazinyl, morpholino, adamantyl, tetrahydroquinolinyl or tetrahydroisoquinolinyl and are optionally substituted with benzyl;~~

R^3 is H or C_{1-4}alkyl;

m is 0 or 1;

R^4 is cyano or halo and is attached to X or X^1;

n is 0;

X and X^1 are each C;

X^2 and X^3 are each CH;

G is N~~, O or S~~;

G^1 is ~~N or~~ CH;

Y is (D)H wherein D is C; and

Z is (E)H wherein E is C;

provided that

~~if G is O or S; then m is 0;~~

if G is N, then m is 1;

if R^1 is -N(H)C(O)OC_{1-4}alkyl ~~or said heterocyclic moiety wherein said heterocyclic moiety contains a nitrogen atom and said nitrogen atom is attached to A^1~~, then A^1 is C_{2-4}alkylene;

if R^2 is -N(H)C(O)OC_{1-4}alkyl ~~or said heterocyclic moiety wherein said heterocyclic moiety contains a nitrogen atom and said nitrogen atom is attached to A^2~~, then A^2 is C_{2-4}alkylene;

if R^1 is -N(H)C(O)O-C_{1-4}alkyl ~~or said heterocyclic moiety~~, then R^2 is H or C_{1-3}alkyl;

if R^2 is -N(H)C(O)O-C_{1-4}alkyl ~~or said heterocyclic moiety~~, then R^1 is H or C_{1-3}alkyl;

~~if R^4 is F and is attached to X and if A^3 is methylene, then A^1-R^1 and A^2-R^2 together with the nitrogen to which they are attached is not N-methyl-piperazinyl; and~~

~~if R^4 is F and is attached to X and if A^3 is methylene, then A^1-R^1 and A^2-R^2 together with the nitrogen to which they are attached is not tetrahydroquinolinyl.~~

41. (currently amended) *Trans*-2-[5-Cyanoindol-3-yl]-1-(*N*,*N*-dimethylaminomethyl)cyclopropane; *Trans*-1-(*N*,*N*-dimethylaminomethyl)-2-[5-fluoroindol-3-yl]cyclopropane; *Trans*-2-[5-Cyanoindol-3-yl]-1-[N,N-methyl-benzylaminomethyl]-cyclopropane; (1*S*,2*S*)-*trans*-1-(N,N-dimethylaminomethyl)-2-[5-fluoroindol-3-yl]-cyclopropane; (1*S*,2*S*)-*trans*-2-[5-cyanoindol-3-yl]-1-(N,N-dimethylaminomethyl)-cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-[N,N-methyl-2-

amino(isopropylcarbamoyl)ethylaminomethyl]-cyclopropane; *trans*-1-(N-Benzlyaminomethyl) -2-[5-cyanoindol-3-yl]-cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-[N-3-phenylpropylaminomethyl]-cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-[N-2-(3-indolyl)ethylaminomethyl]-cyclopropane; ~~*trans*-1-(4-Benzyl-piperidin-1-ylmethyl)-2-[5-cyanoindol-3-yl]-cyclopropane;~~ *trans*-2-[5-Cyanoindol-3-yl]-1-[N,N-dipropylaminomethyl]-cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-[N,N-methyl-phenylethylaminomethyl]-cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-[N-phenylethylamino]-cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-[N-2-(2-methoxyphenyl)ethylamino]-cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-[N-2-(3-methoxyphenyl)ethylamino]-cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-[N-2-(4-methoxyphenyl)ethylamino]-cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-[N-2-phenoxy-ethylamino]-cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-[pyrrolidin-1-yl-methyl]-cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-[N,N-ethyl-2-amino(methylcarbamoyl)ethylamino methyl]-cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-[N,N-ethyl-2-amino(ethylcarbamoyl)ethylaminomethyl]-cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-[N,N-ethyl-2-amino(propyl carbamoyl)ethylamino methyl]-cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-[N,N-ethyl-2-amino(isopropylcarbamoyl) ethylaminomethyl]-cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-[N,N-ethyl-2-amino(methylcarbamoyl)propyl aminomethyl]-cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-[N,N-ethyl-2-amino(ethylcarbamoyl)propylaminom ethyl]-cyclopropane; *Cis*-2-[5-Cyanoindol-3-yl]-1-(*N*,*N*-dimethyl aminomethyl)cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-(*N*-methylaminomethyl)cyclopropane; (1*S*,2*S*)-*trans*-2-[5-Cyanoindol-3-yl]-1-(*N*-methylaminomethyl)cyclopropane; *trans*-3-[2-(1-Dimethylamino-ethyl)-cyclopropyl]-1H-indole-5-carbonitrile; *trans*-3-[2-(1-Pyrrolidin-1-yl-ethyl)-cyclopropyl]-1H-indole-5-carbonitrile; (-)*Cis*-2-[5-Cyanoindol-3-yl]-1-(*N*,*N*-dimethylaminomethyl)cyclopropane; 5-(2-Dimethylaminomethyl-cyclopropyl)-1H-indole-3-carbonitrile; [2-(5,6-Difluoro-1H-indol-3-yl)-cyclopropylmethyl]-dimethyl-amine; *Trans*-2-[5-cyanoindol-3-yl]-1-(3-(N-methylamino)propyl)cyclopropane; S,S-*Trans*-2-[5-Cyanoindol-3-yl]-1-(trimethylammoniummethyl)cyclopropane trifluoroacetate; S,S-*trans*-2-[5-cyano-1-methylindol-3-yl]-1-(*N*,*N*-dimethylamino)-cyclopropane; S,S-*trans*-2-[5-cyano-1-ethylindol-

3-yl]-1-(*N,N*-dimethylamino)-cyclopropane; or 6-(2-Dimethylaminomethyl-cyclopropyl)-1H-indole-3-carbonitrile or pharmaceutically acceptable salts or solvates thereof.

42. (original) A pharmaceutically acceptable formulation comprising a compound according to claim 1.
43. (previously canceled)
44. (previously canceled)
45. (previously canceled)
46. (previously canceled)
47. (previously canceled)
48. (previously canceled)
49. (re-presented - formerly claim 8) A compound according to claim 1 wherein R^4 and R^5 are halo.
50. (re-presented - formerly claim 10) A compound according to claim 1 wherein R^4 is fluoro.
51. (re-presented - formerly claim 12) A compound according to claim 1 wherein R^4 and R^5 are each fluoro.
52. (re-presented - formerly claim 15) A compound according to claim 1 wherein A^3 is C_{1-4}alkylidene.
53. (re-presented - formerly claim 18) A compound according to claim 1 wherein A^4 is methylene.
54. (re-presented - formerly claim 20) A compound according to claim 1 wherein R^4 is attached X.
55. (re-presented - formerly claim 31) A compound according to claim 1 wherein R^2 is H or C_{1-3}alkyl and R^1 is C_{3-6}cycloalkyl, phenyl, -O-phenyl, or -N(H)C(O)O-C_{1-4}alkyl.
56. (re-presented - formerly claim 32) A compound according to claim 1 wherein R^2 is H or C_{1-3}alkyl and R^1 is N(H)C(O)O-C_{1-4}alkyl.
57. (re-presented - formerly claim 33) A compound according to claim 1 wherein R^2 is H or C_{1-3}alkyl and R^1 is C_{3-6}cycloalkyl, phenyl or -O-phenyl.
58. (re-presented - formerly claim 35) A compound according to claim 1 wherein R^1 is H or C_{1-3}alkyl and R^2 is C_{3-6}cycloalkyl, phenyl, -O-phenyl, or -N(H)C(O)O-C_{1-4}alkyl.

59. (re-presented - formerly claim 36) A compound according to claim 1 wherein R^1 is H or C_{1-3}alkyl and R^2 is N(H)C(O)O-C_{1-4}alkyl.

60. (re-presented - formerly claim 37) A compound according to claim 1 wherein R^1 is H or C_{1-3}alkyl and R^2 is C_{3-6}cycloalkyl, phenyl or -O-phenyl.

61. (re-presented - formerly claim 43) A method of treating depression, anxiety disorders, premature ejaculation, urinary incontinence, chronic pain, obsessive-compulsive disorder, feeding disorders, premenstrual dysphoric disorder, hot flashes, panic disorders, posttraumatic stress disorder or social phobia comprising the administration to a human in need thereof an effective amount of a pharmaceutically acceptable formulation comprising a compound according to claim 1.

62. (re-presented - formerly claim 44) A method of treating premature ejaculation comprising the administration to a human in need thereof an effective amount of a pharmaceutically acceptable formulation comprising a compound according to claim 1.

63. (re-presented - formerly claim 47) A method of treating sexual dysfunction in a mammal in need thereof comprising the administration of a pharmaceutically acceptable salt or solvate of a compound according to claim 1 and an erectile dysfunction agent.

64. (re-presented - formerly claim 48) A method of treating sexual dysfunction in a mammal in need thereof comprising the administration of a pharmaceutically acceptable salt or solvate of a compound according to claim 1 and sildenafil.

65. (new) A method of treating sexual dysfunction comprising the administration to a human in need thereof an effective amount of a pharmaceutically acceptable formulation comprising a compound according to claim 1.